{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:30:30Z","timestamp":1789691430792,"version":"4.0.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriasis (PSO) is a chronic immune-mediated inflammatory skin disease characterized by keratinocyte hyperproliferation and dysregulated activation of the IL-23\/IL-17 axis, leading to persistent cutaneous inflammation and substantial disease burden. Comprehensive profiling of circulating inflammatory proteins provides important insights into the systemic immune alterations associated with PSO and its treatment. However, the longitudinal plasma proteomic changes induced by IL-17A blockade remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We quantified the expression levels of 92 inflammation-related proteins in plasma samples from 10 patients with moderate-to-severe PSO before and during secukinumab therapy, as well as from 10 healthy controls (NC), using the Olink Target 96 Inflammation panel. Key differentially expressed proteins were further validated by enzyme-linked immunosorbent assay (ELISA). Longitudinal patterns were assessed using Mfuzz clustering, and functional enrichment analyses were performed to explore the underlying biological pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline plasma proteomic profiles clearly discriminated PSO patients from healthy individuals, with CXCL1, CXCL5, CCL20, and HGF exhibiting the most pronounced alterations and the highest diagnostic performance. Longitudinal analysis revealed a coordinated reduction of multiple inflammatory mediators following IL-17A inhibition, including CCL20, IL-17C, IL-6, and OSM. Mfuzz analysis identified two dominant temporal expression patterns characterized by a progressive decrease in inflammatory and immune-related proteins over the course of secukinumab treatment. Notably, baseline circulating IL-17C levels were significantly positively correlated with disease severity, suggesting its potential as a biomarker of therapeutic response. Functional enrichment analysis indicated that differentially expressed proteins (DEPs) were mainly involved in cytokine\u2013cytokine receptor interaction and IL-17-related signaling pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To our knowledge, this is the first study to characterize the longitudinal plasma proteomic landscape of PSO patients treated with secukinumab using the Olink platform. This work provides molecular evidence for the systemic immunomodulatory effects of IL-17A blockade and highlights candidate circulating biomarkers for disease monitoring and treatment response in PSO. Given the small sample size, these results should be validated in larger, independent cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1806248","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:42:03Z","timestamp":1777009323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal plasma proteomics identifies diagnostic and response-associated inflammatory and immune biomarkers in psoriasis following secukinumab therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongyang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yang","sequence":"additional","affiliation":[{"name":"First Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ma","sequence":"additional","affiliation":[{"name":"First Clinical College of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.69645\/zpgu5302","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"Bmj"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14121169","article-title":"Efficacy and safety of intra-class switching from ixekizumab to secukinumab in patients with plaque psoriasis: a multicenter retrospective study","volume":"14","author":"Bernardini","year":"2024","journal-title":"J Pers Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","article-title":"Mass spectrometry-based proteomics as an emerging tool in clinical laboratories","volume":"20","author":"Birhanu","year":"2023","journal-title":"Clin Proteomics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2021.100168","article-title":"Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis","volume":"20","author":"Wik","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1001\/jama.1987.03390090121046","article-title":"Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis","volume":"14","author":"\u00c5kesson","year":"2023","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03890-6","article-title":"A plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis","volume":"31","author":"Chia","year":"2025","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23274","article-title":"The Olink proteomics profile in nasal secretion of patients with allergic rhinitis","volume":"14","author":"Zeng","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s42004-025-01753-2","article-title":"Comparative evaluation of Olink Explore 3072 and mass spectrometry with peptide fractionation for plasma proteomics","volume":"8","author":"Sissala","year":"2025","journal-title":"Commun Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.85","article-title":"OmicStudio: a composable bioinformatics cloud platform with real-time feedback that can generate high-quality graphs for publication","volume":"2","author":"Lyu","year":"2023","journal-title":"Imeta"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0001-7310(09)73374-5","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000528945","article-title":"Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond Survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","article-title":"A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis","volume":"6","author":"Campa","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Figure","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.sder.2010.03.001","article-title":"New insights in the immunologic basis of psoriasis","volume":"29","author":"Nograles","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3709749","article-title":"Role of neutrophils in psoriasis","volume":"2020","author":"Wang","year":"2020","journal-title":"J Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1057839","article-title":"Genome-wide DNA methylation of Munro's microabscess reveals the epigenetic regulation in the pathogenesis of psoriasis","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26227014","article-title":"Leucosceptoside A from Devil's Claw modulates psoriasis-like inflammation via suppression of the PI3K\/AKT signaling pathway in keratinocytes","volume":"26","author":"Koycheva","year":"2021","journal-title":"Molecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/0115665240307495240605101526","article-title":"HGF, HNRPD, and sFLT1 interfere with the induction of VEGF in patients with severe psoriasis","volume":"25","author":"Sobolev","year":"2025","journal-title":"Curr Mol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13287-023-03239-1","article-title":"Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15395","article-title":"TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis","volume":"8","author":"Sidler","year":"2017","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","first-page":"928461","DOI":"10.1155\/2014\/928461","article-title":"Role of Th17 cells in the pathogenesis of human IBD","volume":"2014","author":"G\u00e1lvez","year":"2014","journal-title":"ISRN Inflammation"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179622","article-title":"Mechanical stretch induced skin regeneration: molecular and cellular mechanism in skin soft tissue expansion","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9722","DOI":"10.1038\/s41598-023-36709-w","article-title":"Intrathecal Th17-driven inflammation is associated with prolonged post-treatment convalescence for patients with Lyme neuroborreliosis","volume":"13","author":"Gyllemark","year":"2023","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201000063","article-title":"An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6\/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease","volume":"32","author":"Comerford","year":"2010","journal-title":"Bioessays"},{"key":"B36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/1817-1737.105718","article-title":"Multiplex protein profiling of bronchoalveolar lavage in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis","volume":"8","author":"Willems","year":"2013","journal-title":"Ann Thorac Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12885-015-1662-6","article-title":"c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence","volume":"15","author":"Al-Maghrabi","year":"2015","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17772","article-title":"Immunoproteomic response to IL-17A blockade in a patient with generalized pustular psoriasis: new insights from plasma Olink profiling","volume":"52","author":"Jeng","year":"2025","journal-title":"J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010555","article-title":"IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15278","article-title":"Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab","volume":"47","author":"Morita","year":"2020","journal-title":"J Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1558","article-title":"Secukinumab treatment does not alter the pharmacokinetics of the cytochrome P450 3A4 substrate midazolam in patients with moderate to severe psoriasis","volume":"106","author":"Bruin","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1738435","article-title":"Circulating IL-17A accumulation reflects effective target blockade with secukinumab in spondyloarthritis","volume":"17","author":"Mart\u00ednez-Moreno","year":"2026","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e223","article-title":"Systemic inflammatory proteomic biomarkers in atopic dermatitis: exploring potential indicators for disease severity","volume":"39","author":"Woo","year":"2024","journal-title":"J Korean Med Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133435","article-title":"Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: potential treatment targets","volume":"14","author":"Barbarroja","year":"2023","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"6423","DOI":"10.1038\/s41598-024-57139-2","article-title":"Analysis and experimental validation of IL-17 pathway and key genes as central roles associated with inflammation in hepatic ischemia-reperfusion injury","volume":"14","author":"Tan","year":"2024","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13223-021-00531-8","article-title":"Early intervention of atopic dermatitis as a preventive strategy for progression of food allergy","volume":"17","author":"Sweeney","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.950973","article-title":"The regulation of skin homeostasis, repair and the pathogenesis of skin diseases by spatiotemporal activation of epidermal mTOR signaling","volume":"10","author":"Wang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.12.004","article-title":"Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application","volume":"146","author":"Ariza","year":"2013","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:42:05Z","timestamp":1777009325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1806248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2026.1806248"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1806248","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"1806248"}}